Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping

Dworzak, Michael; Stolz, Frank; Fröschl, Gertraud; Printz, Dieter; Henn, Traudl; Fischer, Susanna; Fleischer, Christine; Haas, Oskar A.; Fritsch, Gerhard; Gadner, Helmut; Panzer-Grümayer, E. Renate

doi:10.1016/s0301-472x(98)00071-x

Cited by 17 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Details regarding the test standardization, the data acquisition with the CELL Questt software (BD), and the data analysis using the PAINT-A-GATEt software (BD) have been delineated. 12,14 …”

Section: Follow-up and Control Samplesmentioning

confidence: 99%

CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease

et al. 2004

View full text Add to dashboard Cite

Expression of CD99 is higher on immature than on mature T cells. We postulated that this marker could be used to assess minimal residual disease (MRD) in T-lineage acute lymphoblastic leukemia (T-ALL). In diagnostic bone marrow (BM) samples from 27 children with T-ALL, expression of CD99 on leukemic lymphoblasts by flow cytometry was in median 7.7 times higher than on normal T lymphocytes from within the same sample. In 85% of cases, leukemic MFI values were higher than the mean MFI þ 2 s.d. of normal populations. We applied CD99 to study MRD in 39 follow-up samples from 15 consecutive T-ALL patients, and compared the results with those obtained with the well-established MRD-marker terminal deoxynucleotidyl transferase (TdT). Either antibody was combined in four-color flow cytometry with CD7, surfaceCD3, and cytoplasmicCD3. We found that CD99 was a valid complement to TdT in quantifying T-ALL MRD. Given a considerable interpatient variability, CD99 could be favorably used in nine patients, and TdT in other five patients. Both approaches showed a similar very low nonspecific background throughout 12 weeks from diagnosis (in median 0.002% of nucleated BM cells in patients with non-T ALL). We conclude that CD99 is a highly informative tool for MRD detection in T-ALL, bearing the advantage of surface expression in contrast to TdT.

show abstract

Section: Follow-up and Control Samplesmentioning

confidence: 99%

CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Our method was based on a limited antibody panel approach applicable to most patients due to a combination of techniques directed toward investigation of B-cell precursor (BCP) and T-lineage phenotypes, and enabled the detection of one leukemic cell among at least 10 4 normal cells. 4,5,[13][14][15][16][17][18] Patients, materials, and methods…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia

Dworzak

Fröschl

Printz

et al. 2002

Blood

Self Cite

286

235

View full text Add to dashboard Cite

“…The increasing application of FCM was also soon reflected in T-ALL studies. 112,142 A number of investigators 19,20,110,132,[143][144][145] studied the correlation between FCM data and results obtained with PCR analyses, showing good correlation and emphasising the fact that FCM could be used for more patients.…”

Section: Acute Lymphoblastic Leukemiamentioning

confidence: 99%

“…Another approach uses a minimal standardized panel for B-lineage ALL, also defined for normal cells such that it becomes possible to pinpoint abnormal events, 144,147,148 More recently, a large study from the Children's Oncology Group 149 confirmed the efficacy of a two-tube strategy in a series of over 2,000 children with a threshold of 1×10 ) is to differentiate blast cells from hematogones, which can be quite abundant in regenerating bone marrow. The combination CD34/CD19/CD10/CD38 is quite pertinent to differentiate these cell types, based on the difference in fluorescence intensity displayed by hematogones and blasts ( Figure 2B).…”

Section: Acute Lymphoblastic Leukemiamentioning

confidence: 99%

How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet

Béné

Kaeda²

2009

Haematologica

View full text Add to dashboard Cite

Resistance to therapeutic agents is a major factor in the failure of cancer treatments. In leukemia, the resistant cells remaining in the bone marrow and/or peripheral blood constitute minimal residual disease and are detectable by highly sensitive assays when the patient appears to be in complete remission. Early detection of the expansion of residual cells permits clinical intervention with the aim of reversing the proliferation of resistant leukemic cells. Therefore, accurate and precise measurement of minimal residual disease can greatly enhance optimization of oncology patients' clinical management. This notion is supported by a large body of data among chronic myeloid leukemia patients, but minimal residual disease detection and monitoring is increasingly applied to other types of leukemia, and is starting to be a factor in decision-making for some therapeutic trials in childhood acute lymphoblastic leukemia. Here, from the solid ground of minimal residual disease detection in chronic myeloid leukemia, the current state of the art and development of molecular techniques in other leukemias and the growing field of multiparameter flow cytometry are reviewed in two separate parts reporting on the respective advances, advantages and pitfalls of these emerging methods.Key words: minimal residual disease, leukemia, flow cytometry, standardization, monitoring. LeukaemiaNet. Haematologica 2009;94:1135-1150. doi:10.3324/haematol.2008 Citation: Béné MC and Kaeda JS. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European

show abstract

Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping

Cited by 17 publications

References 30 publications

CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease

CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia

How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet

Contact Info

Product

Resources

About